KR20120016051A - 제약 조성물 - Google Patents

제약 조성물 Download PDF

Info

Publication number
KR20120016051A
KR20120016051A KR1020117023612A KR20117023612A KR20120016051A KR 20120016051 A KR20120016051 A KR 20120016051A KR 1020117023612 A KR1020117023612 A KR 1020117023612A KR 20117023612 A KR20117023612 A KR 20117023612A KR 20120016051 A KR20120016051 A KR 20120016051A
Authority
KR
South Korea
Prior art keywords
thio
compound
insulin
halogen atom
glucitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117023612A
Other languages
English (en)
Korean (ko)
Inventor
데이스께 다까하시
사에꼬 우찌다
Original Assignee
다이쇼 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이쇼 세이야꾸 가부시끼가이샤 filed Critical 다이쇼 세이야꾸 가부시끼가이샤
Publication of KR20120016051A publication Critical patent/KR20120016051A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117023612A 2009-04-16 2010-04-16 제약 조성물 Ceased KR20120016051A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
JPJP-P-2009-100210 2009-04-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157009538A Division KR20150046382A (ko) 2009-04-16 2010-04-16 제약 조성물

Publications (1)

Publication Number Publication Date
KR20120016051A true KR20120016051A (ko) 2012-02-22

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117023612A Ceased KR20120016051A (ko) 2009-04-16 2010-04-16 제약 조성물
KR1020157009538A Ceased KR20150046382A (ko) 2009-04-16 2010-04-16 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157009538A Ceased KR20150046382A (ko) 2009-04-16 2010-04-16 제약 조성물

Country Status (30)

Country Link
US (1) US20120040898A1 (https=)
EP (3) EP2419097B1 (https=)
JP (4) JP5077786B2 (https=)
KR (2) KR20120016051A (https=)
CN (7) CN102395364A (https=)
AR (1) AR076317A1 (https=)
AU (1) AU2010237748B2 (https=)
BR (1) BRPI1012539A2 (https=)
CA (1) CA2755392A1 (https=)
CY (2) CY1114703T1 (https=)
DK (2) DK2601949T3 (https=)
ES (2) ES2523408T3 (https=)
HK (6) HK1217301A1 (https=)
HR (2) HRP20131120T1 (https=)
ME (2) ME02015B (https=)
MX (1) MX2011010901A (https=)
MY (3) MY183793A (https=)
NZ (4) NZ606888A (https=)
PH (3) PH12015500235A1 (https=)
PL (2) PL2601949T3 (https=)
PT (2) PT2601949E (https=)
RS (2) RS53056B (https=)
RU (2) RU2532330C2 (https=)
SG (6) SG2014015093A (https=)
SI (2) SI2601949T1 (https=)
SM (1) SMT201500015B (https=)
TW (3) TW201103534A (https=)
UA (2) UA111742C2 (https=)
WO (1) WO2010119990A1 (https=)
ZA (1) ZA201106727B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1202458A1 (en) 2012-05-17 2015-10-02 Vtv治疗有限责任公司 Glucokinase activator compositions for the treatment of diabetes
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
FI4000608T3 (fi) 2013-04-18 2026-01-21 Boehringer Ingelheim Int Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
JP6467583B2 (ja) * 2015-02-27 2019-02-13 ジ アサン ファウンデーション Ｄｐｐ−４の抑制剤を含む弁膜石灰化の予防または治療用の組成物
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2002083066A2 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
RU2434862C2 (ru) * 2006-06-29 2011-11-27 Тайсо Фармасьютикал Ко., Лтд. С-фенил-1-тиоглюцитолы
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
AU2007316613B2 (en) * 2006-11-09 2013-11-28 Boehringer Ingelheim International Gmbh Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션

Also Published As

Publication number Publication date
EP2601949A2 (en) 2013-06-12
JP5910711B2 (ja) 2016-04-27
NZ606888A (en) 2014-07-25
SG175154A1 (en) 2011-11-28
BRPI1012539A2 (pt) 2016-03-29
JP6066144B2 (ja) 2017-01-25
JP2013006854A (ja) 2013-01-10
EP2601949B1 (en) 2014-10-29
EP2601949A3 (en) 2013-09-18
HK1217301A1 (zh) 2017-01-06
MY183793A (en) 2021-03-16
CY1114703T1 (el) 2016-10-05
CN102395364A (zh) 2012-03-28
EP2419097A1 (en) 2012-02-22
PH12019500961A1 (en) 2020-08-03
CN105434430A (zh) 2016-03-30
UA111742C2 (uk) 2016-06-10
RU2011146335A (ru) 2013-05-27
SG2014012553A (en) 2014-05-29
CN105477639A (zh) 2016-04-13
PT2601949E (pt) 2014-11-12
PH12015500235B1 (en) 2015-12-02
ME01555B (me) 2014-04-20
SI2419097T1 (sl) 2014-01-31
CN105343060A (zh) 2016-02-24
AU2010237748A1 (en) 2011-10-20
ES2523408T3 (es) 2014-11-25
TW201622720A (zh) 2016-07-01
JP2012524710A (ja) 2012-10-18
RS53761B1 (sr) 2015-06-30
PL2601949T3 (pl) 2015-04-30
ES2431300T3 (es) 2013-11-25
SG2014014807A (en) 2014-05-29
CY1115907T1 (el) 2017-01-25
RU2014121260A (ru) 2015-12-10
EP2829271A2 (en) 2015-01-28
EP2829271A3 (en) 2015-05-27
SMT201500015B (it) 2015-03-05
PH12015500235A1 (en) 2015-12-02
JP5077786B2 (ja) 2012-11-21
TW201500043A (zh) 2015-01-01
RU2532330C2 (ru) 2014-11-10
CN105343871A (zh) 2016-02-24
CA2755392A1 (en) 2010-10-21
PL2419097T3 (pl) 2014-02-28
NZ595314A (en) 2013-03-28
SG2014015093A (en) 2014-04-28
PH12019500961B1 (en) 2020-08-03
SI2601949T1 (sl) 2014-12-31
AU2010237748B2 (en) 2014-10-30
HRP20131120T1 (hr) 2013-12-20
CN105343059A (zh) 2016-02-24
EP2419097B1 (en) 2013-09-25
JP5660094B2 (ja) 2015-01-28
HK1217435A1 (zh) 2017-01-13
NZ623838A (en) 2015-09-25
UA105216C2 (en) 2014-04-25
PH12019500959B1 (en) 2020-06-29
DK2419097T3 (da) 2013-10-28
RS53056B (sr) 2014-04-30
KR20150046382A (ko) 2015-04-29
HK1217302A1 (zh) 2017-01-06
SG2014012462A (en) 2014-05-29
MY156679A (en) 2016-03-15
TW201103534A (en) 2011-02-01
HK1217434A1 (zh) 2017-01-13
CN105343880A (zh) 2016-02-24
US20120040898A1 (en) 2012-02-16
WO2010119990A1 (en) 2010-10-21
JP2015063543A (ja) 2015-04-09
HK1218881A1 (zh) 2017-03-17
DK2601949T3 (da) 2015-01-05
ZA201106727B (en) 2012-11-28
AR076317A1 (es) 2011-06-01
JP2016104775A (ja) 2016-06-09
NZ710575A (en) 2016-06-24
ME02015B (me) 2015-05-20
PH12019500959A1 (en) 2020-06-29
MY182720A (en) 2021-02-03
MX2011010901A (es) 2011-11-01
HRP20141080T1 (hr) 2015-01-02
HK1218871A1 (zh) 2017-03-17
PT2419097E (pt) 2013-10-03
EP2419097A4 (en) 2012-09-05
SG2014012405A (en) 2014-05-29

Similar Documents

Publication Publication Date Title
KR20120016051A (ko) 제약 조성물
EP2275108B1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
MX2009002282A (es) Tratamiento de combinacion para diabetes mellitius.
US20140128402A1 (en) Pharmaceutical combination
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
AU2014221222B2 (en) Pharmaceutical compositions
HK1165292A (en) Pharmaceutical compositions
AU2016202866A1 (en) Pharmaceutical compositions
HK1137345A (en) Combination treatment for diabetes mellitus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150414

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150414

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150414

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150610

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151001

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150610

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I